Cardiac remodeling and diastolic dysfunction in DahlS.Z-Lepr fa/Lepr fa rats: A new animal model of metabolic syndrome

Hypertension Research

Volumn 35, Issue 2, 2012, Pages 186-193

  Murase, Tamayo ^a   Hattori, Takuya ^a   Ohtake, Masafumi ^a   Abe, Mayuna ^b   Amakusa, Yui ^b   Takatsu, Miwa ^a   Murohara, Toyoaki ^a   Nagata, Kohzo ^b  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

Author keywords

cardiac hypertrophy; diastolic dysfunction; metabolic syndrome; myocardial fibrosis; salt sensitive hypertension

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DAHL SALT SENSITIVE RAT; DIASTOLIC DYSFUNCTION; DIET RESTRICTION; DISEASE MODEL; ECHOCARDIOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; INSULIN BLOOD LEVEL; MALE; METABOLIC SYNDROME X; MYOCARDITIS; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; RAT; SUBCUTANEOUS FAT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; ZUCKER RAT;

AGING; ANIMALS; BLOOD PRESSURE; BODY WEIGHT; CELL SIZE; DIASTOLE; DISEASE MODELS, ANIMAL; FEMALE; FIBROSIS; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; METABOLIC SYNDROME X; MYOCARDITIS; MYOCYTES, CARDIAC; OBESITY; OXIDATIVE STRESS; RATS; RATS, INBRED DAHL; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, LEPTIN; SUPEROXIDES; SURVIVAL; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84856752080     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2011.157     Document Type: Article

References (50)

1. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111: 1448-1454. (Pubitemid 40396812)
2. Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann NY Acad Sci 1999; 892: 146-154.
3. Mathieu P, Poirier P, Pibarot P, Lemieux I, Despres JP. Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease. Hypertension 2009; 53: 577-584.
4. Ren J, Pulakat L, Whaley-Connell A, Sowers JR. Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease. J Mol Med 2010; 88: 993-1001.
5. Wong CY, O'Moore-Sullivan T, Fang ZY, Haluska B, Leano R, Marwick TH. Myocardial and vascular dysfunction and exercise capacity in the metabolic syndrome. Am J Cardiol 2005; 96: 1686-1691. (Pubitemid 41790392)
6. Grandi AM, Maresca AM, Giudici E, Laurita E, Marchesi C, Solbiati F, Nicolini E, Guasti L, Venco A. Metabolic syndrome and morphofunctional characteristics of the left ventricle in clinically hypertensive nondiabetic subjects. Am J Hypertens 2006; 19: 199-205. (Pubitemid 43350174)
7. Carroll JF, Zenebe WJ, Strange TB. Cardiovascular function in a rat model of dietinduced obesity. Hypertension 2006; 48: 65-72. (Pubitemid 44297526)
8. Matsui H, Ando K, Kawarazaki H, Nagae A, Fujita M, Shimosawa T, Nagase M, Fujita T. Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder. Hypertension 2008; 52: 287-294.
9. Hattori T, Murase T, Ohtake M, Inoue T, Tsukamoto H, Takatsu M, Kato Y, Hashimoto K, Murohara T, Nagata K. Characterization of a new animal model of metabolic syndrome: the DahlSZ-Leprfa/Leprfa rat. Nutr Diab 2011; 1: e1; doi:10.1038/nutd.2010.1; published online 31 January 2011.
10. Nagata K, Somura F, Obata K, Odashima M, Izawa H, Ichihara S, Nagasaka T, Iwase M, Yamada Y, Nakashima N, Yokota M. AT1 receptor blockade reduces cardiac calcineurin activity in hypertensive rats. Hypertension 2002; 40: 168-174. (Pubitemid 34840093)
11. Reffelmann T, Kloner RA. Transthoracic echocardiography in rats. Evalution of commonly used indices of left ventricular dimensions, contractile performance, and hypertrophy in a genetic model of hypertrophic heart failure (SHHF-Mcc-facp-Rats) in comparison with Wistar rats during aging. Basic Res Cardiol 2003; 98: 275-284. (Pubitemid 37107654)
12. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083. (Pubitemid 9091990)
13. Tei C, Ling LH, Hodge DO, Bailey KR, Oh JK, Rodeheffer RJ, Tajik AJ, Seward JB. New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function-a study in normals and dilated cardiomyopathy. J Cardiol 1995; 26: 357-366. (Pubitemid 26011184)
14. Wang CT, Navar LG, Mitchell KD. Proximal tubular fluid angiotensin II levels in angiotensin II-induced hypertensive rats. J Hypertens 2003; 21: 353-360. (Pubitemid 36269707)
15. Mitchell KD, Bagatell SJ, Miller CS, Mouton CR, Seth DM, Mullins JJ. Genetic clamping of renin gene expression induces hypertension and elevation of intrarenal Ang II levels of graded severity in Cyp1a1-Ren2 transgenic rats. J Renin Angiotensin Aldosterone Syst 2006; 7: 74-86. (Pubitemid 44383501)
16. Miyachi M, Yazawa H, Furukawa M, Tsuboi K, Ohtake M, Nishizawa T, Hashimoto K, Yokoi T, Kojima T, Murate T, Yokota M, Murohara T, Koike Y, Nagata K. Exercise training alters left ventricular geometry and attenuates heart failure in dahl salt-sensitive hypertensive rats. Hypertension 2009; 53: 701-707.
17. Kato MF, Shibata R, Obata K, Miyachi M, Yazawa H, Tsuboi K, Yamada T, Nishizawa T, Noda A, Cheng XW, Murate T, Koike Y, Murohara T, Yokota M, Nagata K. Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension: role of activation of AMP-activated protein kinase and inhibition of Akt. J Hypertens 2008; 26: 1669-1676.
18. Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H, Kato T, Izawa H, Murohara T, Yokota M. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 2006; 47: 656-664. (Pubitemid 43740235)
19. Elmarakby AA, Loomis ED, Pollock JS, Pollock DM. NADPH oxidase inhibition attenuates oxidative stress but not hypertension produced by chronic ET-1. Hypertension 2005; 45: 283-287. (Pubitemid 40179973)
20. Miyata K, Rahman M, Shokoji T, Nagai Y, Zhang GX, Sun GP, Kimura S, Yukimura T, Kiyomoto H, Kohno M, Abe Y, Nishiyama A. Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol 2005; 16: 2906-2912. (Pubitemid 44743488)
21. Somura F, Izawa H, Iwase M, Takeichi Y, Ishiki R, Nishizawa T, Noda A, Nagata K, Yamada Y, Yokota M. Reduced myocardial sarcoplasmic reticulum Ca(2+)-ATPase mRNA expression and biphasic force-frequency relations in patients with hypertrophic cardiomyopathy. Circulation 2001; 104: 658-663. (Pubitemid 32738519)
22. Sakata Y, Yamamoto K, Mano T, Nishikawa N, Yoshida J, Hori M, Miwa T, Masuyama T. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of Angiotensin-converting enzyme inhibitor. Circulation 2004; 109: 2143-2149. (Pubitemid 38620225)
23. Yamada T, Nagata K, Cheng XW, Obata K, Saka M, Miyachi M, Naruse K, Nishizawa T, Noda A, Izawa H, Kuzuya M, Okumura K, Murohara T, Yokota M. Long-term administration of nifedipine attenuates cardiac remodeling and diastolic heart failure in hypertensive rats. Eur J Pharmacol 2009; 615: 163-170.
24. Verma S, Leung YM, Yao L, Battell M, Dumont AS, McNeill JH. Hyperinsulinemia superimposed on insulin resistance does not elevate blood pressure. Am J Hypertens 2001; 14: 429-432. (Pubitemid 32417598)
25. Johnson PR, Stern JS, Horwitz BA, Harris Jr RE, Greene SF. Longevity in obese and lean male and female rats of the Zucker strain: prevention of hyperphagia. Am J Clin Nutr 1997; 66: 890-903. (Pubitemid 27415574)
26. Kotsis V, Stabouli S, Papakatsika S, Rizos Z, Parati G. Mechanisms of obesity-induced hypertension. Hypertens Res 2010; 33: 386-393.
27. Dhuper S, Abdullah RA, Weichbrod L, Mahdi E, Cohen HW. Association of Obesity and Hypertension With Left Ventricular Geometry and Function in Children and Adolescents. Obesity (Silver Spring) 2010; 19: 128-133; e-pub ahead of print June 2010.
28. Ahmed MS, Oie E, Vinge LE, Yndestad A, Oystein Andersen G, Andersson Y, Attramadal T, Attramadal H. Connective tissue growth factor-a novel mediator of angiotensin II-stimulated cardiac fibroblast activation in heart failure in rats. J Mol Cell Cardiol 2004; 36: 393-404. (Pubitemid 38316944)
29. Kuwahara F, Kai H, Tokuda K, Takeya M, Takeshita A, Egashira K, Imaizumi T. Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension 2004; 43: 739-745. (Pubitemid 38405580)
30. Meldrum DR, Cleveland Jr JC, Cain BS, Meng X, Harken AH. Increased myocardial tumor necrosis factor-alpha in a crystalloid-perfused model of cardiac ischemiareperfusion injury. Ann Thorac Surg 1998; 65: 439-443. (Pubitemid 28083341)
31. Hogye M, Mandi Y, Csanady M, Sepp R, Buzas K. Comparison of circulating levels of interleukin-6 and tumor necrosis factor-alpha in hypertrophic cardiomyopathy and in idiopathic dilated cardiomyopathy. Am J Cardiol 2004; 94: 249-251. (Pubitemid 38902885)
32. Jialal I, Devaraj S, Venugopal SK. Oxidative stress, inflammation, and diabetic vasculopathies: the role of alpha tocopherol therapy. Free Radic Res 2002; 36: 1331-1336. (Pubitemid 35469520)
33. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114: 1752-1761. (Pubitemid 40385531)
34. Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh K, Colucci WS. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 2002; 34: 379-388. (Pubitemid 37163454)
35. Adachi T, Weisbrod RM, Pimentel DR, Ying J, Sharov VS, Schoneich C, Cohen RA. S-Glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide. Nat Med 2004; 10: 1200-1207. (Pubitemid 39540436)
36. El-Menyar AA. Cytokines and myocardial dysfunction: state of the art. J Card Fail 2008; 14: 61-74. (Pubitemid 351146639)
37. Gao X, Belmadani S, Picchi A, Xu X, Potter BJ, Tewari-Singh N, Capobianco S, Chilian WM, Zhang C. Tumor necrosis factor-alpha induces endothelial dysfunction in Lepr(db) mice. Circulation 2007; 115: 245-254. (Pubitemid 46105724)
38. Plenz G, Song ZF, Reichenberg S, Tjan TD, Robenek H, Deng MC. Left-ventricular expression of interleukin-6 messenger-RNA higher in idiopathic dilated than in ischemic cardiomyopathy. Thorac Cardiovasc Surg 1998; 46: 213-216. (Pubitemid 28429539)
39. Newman WH, Castresana MR, Webb JG, Detmer K, Wang Z. Isoproterenol inhibits transcription of cardiac cytokine genes induced by reactive oxygen intermediates. Anesthesiology 2002; 96: 947-954. (Pubitemid 34266690)
40. Srivastava S, Vladykovskaya EN, Haberzettl P, Sithu SD, D'Souza SE, States JC. Arsenic exacerbates atherosclerotic lesion formation and inflammation in ApoER/Fmice. Toxicol Appl Pharmacol 2009; 241: 90-100.
41. Boustany CM, Bharadwaj K, Daugherty A, Brown DR, Randall DC, Cassis LA. Activation of the systemic and adipose renin-angiotensin system in rats with dietinduced obesity and hypertension. Am J Physiol Regul Integr Comp Physiol 2004; 287: R943-R949. (Pubitemid 39280483)
42. Morimoto A, Uzu T, Fujii T, Nishimura M, Kuroda S, Nakamura S, Inenaga T, Kimura G. Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet 1997; 350: 1734-1737. (Pubitemid 28036672)
43. Duffy SJ, Biegelsen ES, Eberhardt RT, Kahn DF, Kingwell BA, Vita JA. Low-renin hypertension with relative aldosterone excess is associated with impaired NO-mediated vasodilation. Hypertension 2005; 46: 707-713. (Pubitemid 43186742)
44. Lamounier-Zepter V, Rotthoff T, Ansurudeen I, Kopprasch S, Scherbaum WA, Ehrhart-Bornstein M, Bornstein SR. Increased aldosterone/renin quotient in obese hypertensive women: a novel role for low-density lipoproteins? Horm Metab Res 2006; 38: 471-475. (Pubitemid 44298778)
45. Fujita T. Mineralocorticoid receptors, salt-sensitive hypertension, and metabolic syndrome. Hypertension 2010; 55: 813-818.
46. Nagase M, Fujita T. Mineralocorticoid receptor activation in obesity hypertension. Hypertens Res 2009; 32: 649-657.
47. Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H, Miyoshi J, Takai Y, Fujita T. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med 2008; 14: 1370-1376.
48. Nagata K. Mineralocorticoid antagonism and cardiac hypertrophy. Curr Hypertens Rep 2008; 10: 216-221.
49. Aoyama T, Matsui T, Novikov M, Park J, Hemmings B, Rosenzweig A. Serum and glucocorticoid-responsive kinase-1 regulates cardiomyocyte survival and hypertrophic response. Circulation 2005; 111: 1652-1659. (Pubitemid 40525165)
50. Nagase M, Yoshida S, Shibata S, Nagase T, Gotoda T, Ando K, Fujita T. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol 2006; 17: 3438-3446. (Pubitemid 44865286)